Where Halozyme Therapeutics Stands With Analysts
Portfolio Pulse from Benzinga Insights
Analysts have provided mostly bullish ratings for Halozyme Therapeutics (NASDAQ:HALO) in the last quarter, with an average price target of $57.83, indicating a potential upside from the current price of $39.14. The average price target has increased by 5.78% from the previous average of $54.67.
September 08, 2023 | 1:00 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Analysts have a bullish outlook on Halozyme Therapeutics, with a higher average price target indicating potential growth.
The bullish ratings and increased price target from analysts suggest a positive outlook for Halozyme Therapeutics. This could potentially lead to an increase in the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100